CR Bard CE-marks Memotherm carotid stent:
This article was originally published in Clinica
CR Bard has CE-marked its nitinol Memotherm carotid stent. The device is designed to self expand once it is inserted and conform to the artery. The company believes this will help to contain the build-up of artheroscleroic plaque which can lead to a stroke. The stent's thermoelastic properties also prevent deformation which might be caused by external compression in the neck. Carotid artery disease is one of the major precursors to ischemic stroke in the US. According to Murray Hill, New Jersey-based Bard, carotid artery stenting provides a less invasive and less expensive way of treating this disease.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.